Lys-MDMA

Lys-MDMA, or lysine-MDMA, also known as N--MDMA, is an intended prodrug of MDMA which was being investigated for possible use as a pharmaceutical drug in the treatment of psychiatric disorders. Structurally, lys-MDMA is to MDMA as lisdexamfetamine is to dextroamphetamine As of August 2024, a phase 1 clinical trial comparing MDMA, MDA, lys-MDMA, and lys-MDA has been conducted and completed. Lys-MDMA was being developed by MindMed.
The published phase 1 clinical trial unexpectedly found that lys-MDMA does not convert into MDMA in humans and is completely inactive. This is in contrast to lisdexamfetamine and lys-MDA, where are converted into dextroamphetamine and MDA, respectively. The lack of conversion was attributed to steric hindrance caused by the N-methyl group of lys-MDMA.